In spite of its known role in the housekeeping process of splicing, this component of the U2 snRNP spliceosome is the target of antitumor drugs [26,27], which suggests that SF3B1 is a bona fide target of driving mutations in CLL. The gene discussed is SF3B1; the disease is B-cell chronic lymphocytic leukemia.